Skip to main content
. 2018 Jun 3;176(8):1024–1037. doi: 10.1111/bph.14336

Figure 2.

Figure 2

Novel immunoresolvents biosynthesized from n‐3 docosapentaenoic. In the vasculature, n‐3 docosapentaenoic acid is the substrate for conversion, by endothelial COX‐2, to 13‐HDPA that is then donated to neutrophils and converted to RvT that display potent protective actions in infectious inflammation (Dalli et al., 2015a). The n‐3 docosapentaenoic is also converted by leukocytes to 17‐HpDHA that is a precursor to RvDn‐3 DPA and PDn‐3 DPA. Conversion of n‐3 DPA via 14‐lipoxygenation yields 14‐HpDPA that is converted to MaRn‐3 DPA. Each of these mediator families displays potent leukocyte‐directed and host‐protective actions (Dalli et al., 2013; Gobbetti et al., 2017).